DITOLYL GUANIDINE ANALOGS AS ANTIPSYCHOTIC DRUGS

该项目的目标是开发一种新的药物治疗， 这种精神分裂症产生锥体外系的可能性很小， 副作用迟发性运动障碍或镇静 一个共识已经出现 从动物和人类的受体研究和行为实验中， σ受体可能介导一些药物诱导的（苯并吗喃，PCP） 拟精神病的影响，以及负责的行动， 氟哌啶醇和一些新提出的抗精神病药物。 我们有独家 全球范围内的专利许可权的一系列类似物的二邻- 甲苯基胍（DTG），最具选择性和有效的σ受体之一 配体。 在这个项目的第一阶段，我们成功地描述了最有前途的 用于受体特异性和血脑屏障通透性的DTG类似物。 有了几种化合物，我们还扩大了化学合成， 在动物试验中，产生了抗精神病作用的证据， 副作用责任。 本项目第二阶段的目标是进一步表征电极导线 生物化学和生理学上的化合物， 发展过程 与此同时，我们将启动开发 获得IND所需的步骤。这些步骤将包括散装化学品 合成、化学测定法的开发、药理学安全性和 代谢研究和全面毒性测试。

The goal of this project is to develop a novel drug treatment for schizophrenia that would have minimal liability to produce extrapyramidal side effects, tardive dyskinesia, or sedation. A consensus has emerged from receptor studies and behavioral experiments in animals and humans, that the sigma receptor may mediate some drug-induced (benzomorphan, PCP) psychotomimetic effects as well as be responsible for the actions of haloperidol and some newly proposed antipsychotic drugs. We have exclusive world-wide patent licensing rights to a series of analogs of Di-ortho- tolyl-guanidine (DTG), one of the most selective and potent sigma receptor ligands. In Phase I this project we succeeded in characterizing the most promising DTG analogs for receptor specificity and blood brain barrier permeability. With several of the compounds, we also scaled up the chemical synthesis and produced evidence, in animal tests, of antipsychotic effect with minimal side effect liability. The goals of Phase II of this project are to further characterize the lead compounds biochemically and physiologically in ways that will aid the development process. At the same time we will initiate the development steps necessary to obtain an IND. These will include bulk chemical synthesis, development of a chemical assay, pharmacology safety and metabolism studies and full-scale toxicity testing.